Clinical Trials
19 trialsNCT07560865 2026-05-01
First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma
Masonic Cancer Center, University of Minnesota
Phase 1 Recruiting
NCT04678648 2026-03-18
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
RasCal Therapeutics, Inc.
Phase 1 Recruiting
NCT03586661 2026-03-11
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT07137871 2025-10-31
Clinical Trial of Avasopasem in Patients With Metastatic Hormone Receptor Positive Breast Cancer With Progression on a CDK 4/6 Inhibitor and Hormonal Therapy
The University of Texas Health Science Center at San Antonio
Phase 1 Recruiting
NCT05153330 2025-07-03
Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutations), DLBCL, MM, and CLL/SLL
Biomea Fusion Inc.
Phase 1 Terminated
NCT02766699 2025-06-03
CerebralEDV
Engeneic Pty Limited
Phase 1 Completed
NCT01543763 2025-03-21
Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors
University of California, San Francisco
Phase 1 Completed
NCT02043847 2024-11-13
BMT-03
University of Illinois at Chicago
Phase 1 Completed
NCT06622174 2024-10-02
PROMISE
Centre hospitalier de l'Université de Montréal (CHUM)
Phase 1 Not yet recruiting
NCT03546426 2024-10-01
MESOVAX
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Phase 1 Active not recruiting
NCT03422393 2024-07-05
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
University of California, San Diego
Phase 1 Active not recruiting
NCT02135406 2023-06-22
CART-19 for Multiple Myeloma
University of Pennsylvania
Phase 1 Completed
NCT04005144 2022-10-17
Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
University of California, San Francisco
Phase 1 Terminated
NCT00108056 2019-12-05
Enzastaurin to Treat Recurrent Brain Tumor
National Institutes of Health Clinical Center (CC)
Phase 1 Terminated
NCT00272350 2019-12-05
ZD6474 to Treat Advanced Brain Cancer in Patients
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02189343 2019-11-21
Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma
Celgene
Phase 1 Completed
NCT02586987 2019-11-18
A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours
AstraZeneca
Phase 1 Completed
NCT01355965 2017-09-19
Autologous Redirected RNA Meso-CIR T Cells
University of Pennsylvania
Phase 1 Completed
NCT01692262 2014-06-19
PYRUS
AstraZeneca
Phase 1 Completed